Olympus to Acquire BioProtect in $270M Prostate Cancer Care Deal

Deal Summary

Olympus announced it will acquire BioProtect for $270 million, aiming to strengthen its prostate cancer treatment portfolio. The acquisition focuses on BioProtect's Balloon Spacer technology, which creates temporary space between the prostate and nearby organs during radiation therapy.